Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women
- 9 October 2012
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 51 (12) , 809-822
Abstract
Background and Objectives A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-infected women demonstrated differing degrees of female genital tract penetration among antiretrovirals. These blood plasma (BP) and cervicovaginal fluid (CVF) data were co-modelled for four antiretrovirals with varying CVF exposures. Methods Six paired BP and CVF samples were collected over 24 h, and antiretroviral concentrations determined using validated liquid chromatography (LC) with UV detection or LC-mass spectrometry analytical methods. For each antiretroviral, a BP model was fit using Bayesian estimation (ADAPT5), followed by addition of a CVF model. The final model was chosen based on graphical and statistical output, and then non-linear mixed-effects modelling using S-ADAPT was performed. Population mean parameters and their variability are reported. Model-predicated area under the concentration–time curve during the dosing interval (AUCτ) and exposure ratios of CVF AUCτ:BP AUCτ were calculated for each drug. Results The base model uses first-order absorption with a lag time, a two-compartment model, and a series of transit compartments that transfer the drug from BP to CVF. Protein-unbound drug transfers into CVF for efavirenz and atazanavir; total drug transfers for lamivudine and tenofovir. CVF follows a one-compartment model for efavirenz and atazanavir, and a two-compartment model for lamivudine and tenofovir. As expected, inter-individual variability was high. Model-predicted CVF AUCτ:BP AUCτ ratios are consistent with published results. Conclusions This is the first pharmacokinetic modelling of antiretroviral disposition in BP and CVF. These models will be further refined with tissue data, and used in clinical trials simulations to inform future studies of HIV pre-exposure prophylaxis in women.Keywords
This publication has 35 references indexed in Scilit:
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Residual HIV-1 RNA and HIV-1 Dna Production in the Genital Tract Reservoir of Women Treated with Haart: The Prospective Anrs Ep24 Gynodyn StudyAntiviral Therapy, 2011
- Cervicovaginal Shedding of HIV Type 1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal MicrobiotaAIDS Research and Human Retroviruses, 2011
- Elevated Cervical White Blood Cell Infiltrate Is Associated with Genital HIV Detection in a Longitudinal Cohort of Antiretroviral Therapy–Adherent WomenThe Journal of Infectious Diseases, 2010
- Discordance in HIV‐1 viral loads and antiretroviral drug concentrations comparing semen and blood plasmaHIV Medicine, 2009
- Determinants of HIV-1 shedding in the genital tract of womenThe Lancet, 2001
- Selection of Drug‐Resistant Variants in the Female Genital Tract of Human Immunodeficiency Virus Type 1–Infected Women Receiving Antiretroviral TherapyThe Journal of Infectious Diseases, 2000
- The Effects of Protease Inhibitor Therapy on Human Immunodeficiency Virus Type 1 Levels in Semen (AIDS Clinical Trials Group Protocol 850)The Journal of Infectious Diseases, 2000
- Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000
- Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNAAIDS, 2000